Collplant and stratasys announce pre-clinical study for regenerative commercial-sized breast implants

3d printed breast implants consisting of 200cc in volume of collplant's rhcollagen-based bioinks produced on a stratasys' origin® printer to be tested technology innovation addresses a $3.0 billion market opportunity study to focus on ability of implants to grow natural breast tissue and completely degrade over time  rehovot, israel & eden prairie, minn. , aug. 19, 2024 /prnewswire/ -- in a significant step in the advancement of regenerative medicine, collplant biotechnologies (nasdaq: clgn) and stratasys ltd.
CLGN Ratings Summary
CLGN Quant Ranking